Search Results - "Gilor, C."

One hundred years of insulin: Is it time for smart? by Gilor, C., Fleeman, L. M.

“…Smarter understanding of diabetes pathophysiology and pharmacology of insulin therapy can lead to better clinical outcomes. Rather than looking for an insulin…”
Get full text

The glucagon-receptor antagonist MK-3577 reduces glucagon-stimulated plasma glucose and insulin concentrations in metabolically healthy overweight cats by Mott, J, Celly, C, Glock, R, Gilor, C

“…•MK-3577, a glucagon receptor antagonist has about a 15-hour half-life in cats.•MK-3577 treated cats exhibit blunted glucagon-induced rise of glucose and…”
Get full text

What's in a Name? Classification of Diabetes Mellitus in Veterinary Medicine and Why It Matters by Gilor, C., Niessen, S.J.M., Furrow, E., DiBartola, S.P.

“…Diabetes Mellitus (DM) is a syndrome caused by various etiologies. The clinical manifestations of DM are not indicative of the cause of the disease, but might…”
Get full text

Machine learning algorithm as a diagnostic tool for hypoadrenocorticism in dogs by Reagan, K.L., Reagan, B.A., Gilor, C.

“…Canine hypoadrenocorticism (CHA) is a life-threatening condition that affects approximately 3 of 1,000 dogs. It has a wide array of clinical signs and is known…”
Get full text

Gut microbiota promoting propionic acid production accompanies caloric restriction-induced intentional weight loss in cats by Rowe, J. C., Winston, J. A., Parker, V. J., McCool, K. E., Suchodolski, J. S., Lopes, R., Steiner, J. M., Gilor, C., Rudinsky, A. J.

“…Rodent models and human clinical studies have shown gut microbiota-derived short-chain fatty acids (SCFAs) play roles in obesity and insulin resistance. These…”
Get full text

Consistency of faecal scoring using two canine faecal scoring systems by Cavett, C. L., Tonero, M., Marks, S. L., Winston, J. A., Gilor, C., Rudinsky, A. J.

“…Objective To determine the agreement of canine faecal scoring between individuals with different levels of experience using two available faecal scoring…”
Get full text

Dietary management of presumptive protein‐losing enteropathy in Yorkshire terriers by Rudinsky, A. J., Howard, J. P., Bishop, M. A., Sherding, R. G., Parker, V. J., Gilor, C.

“…Objectives To describe the clinical outcome of dietary management of Yorkshire terriers with protein‐losing enteropathy without…”
Get full text

Pharmacodynamics and pharmacokinetics of insulin detemir and insulin glargine 300 U/mL in healthy dogs by Fink, H., Herbert, C., Gilor, C.

“…Insulin glargine 300 U/mL and insulin detemir are synthetic long-acting insulin analogs associated with minimal day-to-day variability or episodes of…”
Get full text

The effect of capromorelin on glycemic control in healthy dogs by Pascutti, K.M., O'Kell, A.L., Hill, R.C., Castro, R.A., Salute, M.E., Gilor, C.

“…•In healthy dogs, capromorelin causes an increase in post-prandial blood glucose concentrations.•In healthy dogs, capromorelin does not overtly suppress…”
Get full text

The effect of the ghrelin-receptor agonist capromorelin on glucose metabolism in healthy cats by Pires, J., Greathouse, R.L., Quach, N., Huising, M.O., Crakes, K.R., Miller, M., Gilor, C.

“…Somatostatin secretion from islet delta cells is important in maintaining low glycemic variability (GV) by providing negative feedback to beta cells and…”
Get full text

Re‐evaluation of the low‐dose dexamethasone suppression test in dogs by Lim, L., Hulsebosch, S. E., Gilor, C., Reagan, K. L., Kopecny, L., Maggiore, A. D., Phillips, K. L., Kass, P. H., Vernau, W., Nelson, R. W.

“…Objectives This study aims to re‐evaluate the low‐dose dexamethasone suppression test 8‐hour cortisol cut‐point for the diagnosis of hypercortisolism in dogs…”
Get full text

Therapy of Canine Hyperlipidemia with Bezafibrate by De Marco, V., Noronha, K.S.M., Casado, T.C., Nakandakare, E.R., Florio, J.C., Santos, E.Z., Gilor, C.

“…Background Bezafibrate (BZF) is effective in the treatment of hypertriglyceridemia in human patients, but there are no data on its use in dogs. Objective To…”
Get full text

Comparison of pharmacodynamics between insulin glargine 100 U/mL and insulin glargine 300 U/mL in healthy cats by Saini, N.K., Wasik, B., Pires, J., Leale, D.M., Quach, N., Culp, W.T.N., Samms, R.J., Johnson, A.E., Owens, J.G., Gilor, C.

“…Insulin glargine (IGla) is a synthetic human-recombinant insulin analog that is used routinely in people as a q24h basal insulin. The 300 U/mL (U300)…”
Get full text

Comparison of pharmacodynamics and pharmacokinetics of insulin degludec and insulin glargine 300 U/mL in healthy cats by Gilor, C., Culp, W., Ghandi, S., do Carmo Emidio e Silva, J.A., Ladhar, A., Hulsebosch, S.E.

“…Insulin glargine 300 U/mL (IGla-U300) and insulin degludec (IDeg) are synthetic insulin analogs designed as basal insulin formulations. In people, IGla-U300 is…”
Get full text

Duration of fasting but not diurnal variation affects the response to glucagon in healthy cats by Gilor, C., Glock, R., Gilor, S.

“…The role of glucagon disturbances in diabetes is increasingly recognized. Glucagon stimulation tests (GSTs) have been described in cats previously, but…”
Get full text

The effect of diet, adiposity, and weight loss on the secretion of incretin hormones in cats by McCool, K.E., Rudinsky, A.J., Parker, V.J., Herbert, C.O., Gilor, C.

“…Degree of adiposity and dietary macronutrient composition affect incretin hormone secretion in humans and mice, but little is known about their effect in cats…”
Get full text

Pharmacodynamics and pharmacokinetics of insulin aspart assessed by use of the isoglycemic clamp method in healthy cats by Pipe-Martin, H.N., Fletcher, J.M., Gilor, C., Mitchell, M.A.

“…The objective of this study was to determine the pharmacodynamics (PD) and pharmacokinetics (PK) of insulin aspart in healthy cats following intramuscular (IM)…”
Get full text

Pharmacology of the glucagon-like peptide-1 analog exenatide extended-release in healthy cats by Rudinsky, A.J., Adin, C.A., Borin-Crivellenti, S., Rajala-Schultz, P., Hall, M.J., Gilor, C.

“…Exenatide extended-release (ER) is a microencapsulated formulation of the glucagon-like peptide 1-receptor agonist exenatide. It has a protracted…”
Get full text

Pharmacokinetics and pharmacodynamics of the glucagon-like peptide-1 analog liraglutide in healthy cats by Hall, M.J., Adin, C.A., Borin-Crivellenti, S., Rudinsky, A.J., Rajala-Schultz, P., Lakritz, J., Gilor, C.

“…Glucagon-like peptide-1 (GLP-1) is an intestinal hormone that induces glucose-dependent stimulation of insulin secretion while suppressing glucagon secretion…”
Get full text

Distribution of K and L cells in the feline intestinal tract by Gilor, C., Gilor, S., Graves, T.K., Borst, L.B., Labelle, P., Ridge, T.K., Santoro, D., Dossin, O.

“…Glucose-dependent insulinotropic peptide (GIP), glucagon-like peptide (GLP)-1 and GLP-2 are hormones secreted from specialized K cells (GIP) and L cells…”
Get full text